Concord Biotech

Concord Biotech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Concord Biotech (CONCORDBIO.NS) as of Oct 18, 2026 is 66.74 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 36.66 % — a change of 82.06% (higher).

FCF Conversion

66.74 %

YoY

82.06%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Concord Biotech is 2026 66.74 % . FCF Conversion Rate (FCF/EBITDA) of Concord Biotech was 2025 36.66 % . It decreases by 82.06% higher compared to the previous year.

The Concord Biotech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
-0.37 INR
Jan 1, 2021
-15.91 INR
Jan 1, 2022
29.71 INR
Jan 1, 2023
42.03 INR
Jan 1, 2024
58.35 INR
Jan 1, 2025
36.66 INR
Jan 1, 2026
66.74 INR
The Concord Biotech FCF Conversion history
YEARFCF ConversionYoY
66.74 %+82.06%
36.66 %-37.18%
58.35 %+38.82%
42.03 %+41.48%
29.71 %-286.79%
-15.91 %+4,217.40%
-0.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Concord Biotech Stock analysis

What does Concord Biotech do? Concord Biotech Ltd is a pharmaceutical company headquartered in Ahmedabad, India. It operates in the Health Care sector with a focus on Pharmaceuticals. The company went public via an IPO on August 18, 2023. Concord Biotech develops and manufactures active pharmaceutical ingredients (APIs) using fermentation and semi-synthetic processes. It produces finished formulations and APIs for therapeutic areas including immunosuppressants, anti-bacterial, oncology, and anti-fungal treatments. The company's API portfolio includes Mycophenolate Mofetil, Cyclosporine, Vancomycin Hydrochloride, and others. It also has a pipeline of API products under development such as Polymyxin B and Fidaxomicin. Concord Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Concord Biotech stock

FCF Conversion Rate (FCF/EBITDA) of Concord Biotech is 66.74 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Concord Biotech changed from 36.66 % to 66.74 %, representing a 82.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Concord Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Concord Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Concord Biotech

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Concord Biotech